SAN DIEGO, CA (PRWEB) October 04, 2015
CME Certified Satellite Symposium during IDWeek
will consider emerging options for
Treating Resistant Serious Infections in the Hospital Setting
Jointly Provided by
the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences and ASiM
SAN DIEGO – Infectious disease scientists and clinicians gathering for the annual ID Week conference from October 6-9, 2015 will have an opportunity to learn from experts about emerging research that may revolutionize the treatment of resistant infections. The subject of resistant infections has been a growing concern over the last decade, and though new agents have been approved for use, clinicians continue to be vexed by bacteria and fungi that aren’t eradicated by the most potent therapeutic options.
“It’s not just that bacteria or fungi become resistant,” says Peter G. Pappas, MD, FACP, Professor of Medicine in the Division of Infectious Diseases at UAB School of Medicine. “There is also the problem that efficacious agents that are already available and have demonstrated efficacy are not able to reach maximum dosage levels before being stopped due to complications from IV administration. It seems we may now have an option to deliver clinically effective dosages without using IV, but more research is needed.”
Dr. Pappas will be part of a panel of ID experts who will provide insight and discuss emerging research showing that a unique drug delivery technology – cochleates – may be able to successfully address many of the complications and challenges associated with resistance to current antibacterial and antifungal regimens administered by IV. They will present the research during an industry supported satellite symposium to be held on Wednesday, October 7th from 8-10 PM in the San Diego Convention Center (Room 28ABCD). All attendees of ID Week are welcome at no additional cost.
Topics to be addressed at this exciting symposium, “Current Challenges and Future Directions for the Treatment for Treatment of Serious Microbial Infections in an Era of Increasing Drug Resistance,” include:
- Introduction to the Current Challenges to the Treatment of Microbial Resistance - Edmund C. Tramont, MD, MACP (DCR/NIAID/NIH)
- Challenges for the Treatment of Resistant Fungal Infections - Peter G. Pappas, MD, FACP
- New Directions for the Treatment of Resistant Fungal Infections - J Carl Craft, MD
- Pneumocystis: Clinical Manifestations and Treatment Options - Parag Kumar, PharmD (NIH)
- Mycobacteria Infections: The Critical Problem of Drug Resistance and Treatment - Barry Kreiswirth, PhD
The CME certified satellite symposium is made possible by an educational grant provided to the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences by Matinas Biopharma.
About Rutgers Biomedical and Health Sciences
Rutgers Biomedical and Health Sciences (RBHS) is a major new healthcare education, research, and clinical division of Rutgers, The State University of New Jersey. As a premier, university-based provider of healthcare, RBHS offers excellence in care while advancing health sciences education and research across a range of disciplines. Through basic, translational, and clinical research – spanning the life sciences, physical sciences, and social sciences – RBHS advances knowledge and technology that drive education, medical breakthroughs, and economic development, while improving lives throughout New Jersey and in the global community.
For more information, please visit: http://ccoe.rbhs.rutgers.edu/ or contact Patrick Dwyer at Patrick(dot)Dwyer(at)rutgers(dot)edu.